Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses

Fig. 2

Posterior probability of haloperidol versus placebo for delirium treatment on the primary outcomes. The distribution chart on the right, yellow represents the probability of exceeding the clinical important benefit, while pink represents the probability of being below the clinical important benefit. For the values on the left, yellow represents the benefit values, and pink represents the harm values. Abbreviation: CIB = clnically imporant benefit; CIH = clinically imporant harm. aDotted line indicates clinical important benefit, and solid line indicates no difference. bThe cut-off point for clinically important benefit is −0.02 for risk difference and 0.9 for risk ratio, while the cut-off point for clinically important harm is 0.02 for risk difference and 1.1 for risk ratio

Back to article page

Critical Care

ISSN: 1364-8535